{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"Overall response rate=CR+sCR+VGPR+PR\n\nComplete response (CR), disappearance of monoclonal protein from the blood \\& urine and \\<5% plasma cells in bone marrow \\&disappearance of soft tissue plasmacytomas\n\nStringent complete response (sCR), CR \\& normal free light chain ratio \\& absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\n\nVery good partial response (VGPR), serum and urine monoclonal protein detectable by immunofixation but not on electrophoresis OR \\> 90% reduction in serum monoclonal protein with urine monoclonal protein \\< 100 mg per 24 hours and if present, \\> 50% reduction in the size of soft tissue plasmacytomas\n\nPartial response (PR), \\> 50% reduction in the level of the serum monoclonal protein \\& reduction in urine monoclonal protein \\& \\> 50% reduction in the size of soft tissue plasmacytomas \\& if serum and urine monoclonal protein are unmeasurable and serum free light chain is unmeasurable, a \\> 50% reduction in plasma cells is required","groups":[{"description":"Granix on Day -7 through Day -2.\n\nHDM intravenously (IV) on Day -2.\n\nAutologous stem cell transplantation on Day 0","id":"OG000","title":"Experimental: Granix and High Dose Melphalan (HDM)"},{"description":"HDM intravenously (IV) on Day -2.","id":"OG001","title":"Control: High Dose Melphalan (HDM)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Number of Participants With Overall Response","type":"SECONDARY","unitOfMeasure":"Participants"}